Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the ...

Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...

As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are ...

Sarepta stock plunged again Thursday on a report that the Food and Drug Administration will require additional clinical ...

Stock futures nudged higher on Friday, driven by strong performances from major technology companies and growing optimism over potential trade agreements ahead of the Trump administration’s August ...